IMPORTANT SAFETY INFORMATION

Indication: METROGEL® 1% is indicated for the topical treatment of the inflammatory lesions of rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with METROGEL 1% were nasopharyngitis, upper respiratory tract infection, and headache. Other adverse experiences reported when using topical metronidazole include skin irritation, transient redness, metallic taste, tingling or numbness of the extremities and nausea. Warnings/Precautions: METROGEL 1% should not be used by patients who are allergic to metronidazole or any ingredient in METROGEL 1%. Avoid contact of METROGEL 1% with the eyes as it may cause tearing. METROGEL 1% should be used with caution in patients with evidence of, or a history of, blood dyscrasia, and with patients taking blood thinning agents as they may experience prolonged prothrombin times. METROGEL 1% treatment should be discontinued if numbness or paresthesia of any extremity should occur.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.